{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:18:44Z","timestamp":1778692724401,"version":"3.51.4"},"reference-count":227,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,5]]},"abstract":"Abstract<\/jats:title>\n \n Introduction<\/jats:title>\n Antibody\u2013drug conjugates (ADC) have emerged as an important part of systemic treatment across disease sites. To date, there is no robust pooled prevalence estimate of nausea and vomiting induced by ADCs. Establishing such estimates is essential to determine if ADC-induced nausea and vomiting (ADCINV) represents a clinically significant problem warranting further research into antiemetic prophylaxis. Our aim is to report the prevalence of reported ADCINV across literature.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A systematic search of Medline, Embase, Cochrane CENTRAL and Web of Science was conducted from database inception until September 24, 2025. Articles were included if they reported nausea and\/or vomiting due to ADCs used in cancer treatment, in the abstract. Pooled prevalence was reported. Subgroup analysis was conducted by ADC. Meta-regression was conducted by age and sex. Quality assessment was conducted. Type I error was set at 0.05.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 209 studies with 15,493 patients were included. Thirty-nine percent (95%CI, 36\u201342%) of patients experience any nausea, and 26% (95%CI, 23\u201329%) experience any vomiting. Younger patients are more likely to experience nausea; each 10-year increase in age is associated with a 12% decrease in nausea rates. Higher emetogenic ADCs include trastuzumab deruxtecan, sacituzumab govitecan, brentuximabvedotin and patritumab deruxtecan. Lower emetogenic agents include disitimab vedotin, telisotuzumab vedotin and rovalpituzumab tesirine.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n This is the first study to report prevalence of ADCINV across ADCs. It is a prevalent adverse effect akin to chemotherapy-induced nausea and vomiting that should be viewed as clinically relevant and further investigated to help develop optimal strategies related to antiemetics.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00520-026-10674-2","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T11:43:36Z","timestamp":1777722216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of antibody drug conjugated\u2013induced nausea and vomiting (ADCINV) in patients with cancer"],"prefix":"10.1007","volume":"34","author":[{"given":"Ronald","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Kannout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayden","family":"Blayne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rouhi","family":"Fazelzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Louise","family":"Affronti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On Behalf of the MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"4","key":"10674_CR1","first-page":"307","volume":"5","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307\u201313","journal-title":"Support Care Cancer"},{"issue":"8","key":"10674_CR2","first-page":"505","volume":"31","author":"R Chow","year":"2023","unstructured":"Chow R, Yin LB, Baqri W et al (2023) Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis. Support Care Cancer 31(8):505","journal-title":"Support Care Cancer"},{"issue":"1","key":"10674_CR3","first-page":"53","volume":"32","author":"K Jordan","year":"2023","unstructured":"Jordan K, Chan A, Gralla RJ et al (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation. Support Care Cancer 32(1):53","journal-title":"Support Care Cancer"},{"key":"10674_CR4","doi-asserted-by":"crossref","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2).\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/38458657\/","DOI":"10.1016\/j.esmoop.2023.102195"},{"issue":"1","key":"10674_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K, Li M, Li Y et al (2024) A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers. Mol Cancer 23(1):62","journal-title":"Mol Cancer"},{"issue":"1","key":"10674_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z et al (2025) Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol 18(1):51","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10674_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/PPO.0000000000000627","volume":"28","author":"MA Gouda","year":"2022","unstructured":"Gouda MA, Subbiah V (2022) Strategies for mitigating antibody-drug conjugate related adverse events for precision therapy. Cancer J 28(6):496\u2013507","journal-title":"Cancer J"},{"key":"10674_CR8","volume-title":"Common terminology criteria for adverse events (CTCAE) v5.0","author":"National Cancer Institute","year":"2017","unstructured":"National Cancer Institute (2017) Common terminology criteria for adverse events (CTCAE) v5.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD"},{"key":"10674_CR9","unstructured":"National Cancer Institute (2024) Drugs Approved for Different Types of Cancer. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/cancer-type2024)"},{"issue":"3","key":"10674_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.7326\/ANNALS-24-02189","volume":"178","author":"C Cao","year":"2025","unstructured":"Cao C, Sang J, Arora R et al (2025) Development of prompt templates for large language model\u2013driven screening in systematic reviews. Ann Intern Med 178(3):389\u2013401","journal-title":"Ann Intern Med"},{"key":"10674_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","author":"JPT Higgins","year":"2024","unstructured":"Higgins JPT, Morgan RL, Rooney AA (2024) A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. https:\/\/doi.org\/10.1016\/j.envint.2024.108602","journal-title":"Environ Int"},{"key":"10674_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"10674_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ (2019) RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"10674_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-021-01610-y","volume":"10","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Robvis: an R package and web app for visualising risk-of-bias assessments. Syst Rev 10:79","journal-title":"Syst Rev"},{"issue":"16_suppl","key":"10674_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2025.43.16_suppl.511","volume":"43","author":"RO Abelman","year":"2025","unstructured":"Abelman RO, McLaughlin S, Fell GG et al (2025) A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG\/P) in patients with early-stage triple-negative breast cancer: results from the NeoSTAR trial. J Clin Oncol 43(16_suppl):511","journal-title":"J Clin Oncol"},{"issue":"3","key":"10674_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59030498","volume":"59","author":"\u0130H A\u00e7ar","year":"2023","unstructured":"A\u00e7ar \u0130H, Guvenc B (2023) The use of gemtuzumab ozogamicin as salvage therapy in patients with acute myeloid leukemia: a monocentric real\u2011world experience. Medicina 59(3):498","journal-title":"Medicina"},{"issue":"16_suppl","key":"10674_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6048","volume":"43","author":"W Adkins","year":"2025","unstructured":"Adkins W (2025) Phase II trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2 antibody\u2011drug conjugate. J Clin Oncol 43(16_suppl):6048","journal-title":"J Clin Oncol"},{"issue":"12","key":"10674_CR18","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","volume":"28","author":"A Advani","year":"2010","unstructured":"Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gin\u00e9 E (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 28(12):2085\u20132093","journal-title":"J Clin Oncol"},{"issue":"7","key":"10674_CR19","first-page":"1840","volume":"28","author":"C Aggarwal","year":"2017","unstructured":"Aggarwal C, Redman MW, Lara PN Jr et al (2017) Rovalpituzumab tesirine as a DLL3-targeted antibody-drug conjugate for patients with recurrent small-cell lung cancer: results from a phase I study. Ann Oncol 28(7):1840\u20131847","journal-title":"Ann Oncol"},{"issue":"12","key":"10674_CR20","first-page":"3015","volume":"22","author":"K Almhanna","year":"2016","unstructured":"Almhanna K, Burris HA, Rasco DW et al (2016) A phase I study of TAK-264, an antibody-drug conjugate targeting guanylyl cyclase C, in patients with advanced gastrointestinal malignancies. Clin Cancer Res 22(12):3015\u20133022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10674_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10637-017-0439-y","volume":"35","author":"K Almhanna","year":"2017","unstructured":"Almhanna K, Miron ML, Wright D et al (2017) Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Invest New Drugs 35(2):235\u2013241","journal-title":"Invest New Drugs"},{"issue":"5","key":"10674_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s10637-017-0473-9","volume":"35","author":"K Almhanna","year":"2017","unstructured":"Almhanna K, Wright D, Mercade TM et al (2017) A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs 35(5):634\u2013641","journal-title":"Invest New Drugs"},{"key":"10674_CR23","doi-asserted-by":"crossref","unstructured":"Bai C, Xue J, Zheng Y et al (2025) A phase 1\/2 study of LM-302, an anti-claudin 18.2 antibody-drug conjugate in advanced gastric\/gastroesophageal junction cancer (abstract). J Clin Oncol 43(16_suppl): 4039","DOI":"10.1200\/JCO.2024.42.16_suppl.3028"},{"key":"10674_CR24","first-page":"2909","volume":"130","author":"JH Baird","year":"2017","unstructured":"Baird JH, Verstovsek S, George TI et al (2017) Phase 2 study of brentuximab vedotin in patients with advanced systemic mastocytosis. Blood 130:2909","journal-title":"Blood"},{"key":"10674_CR25","doi-asserted-by":"crossref","unstructured":"Baird R, Chung W-P, Schmid P (2025) Puxitatug samrotecan (P-Sam, AZD8205) in patients with HR+\/HER2- breast cancer: first-in-human Phase I\/IIa dose escalation and expansion (abstract 300MO). ESMO Open\u00a0[to be assigned]([to be assigned]): 300MO.\u00a0https:\/\/www.esmoopen.com\/article\/S2059-7029(25)00741-0\/fulltext","DOI":"10.1016\/j.esmoop.2025.104872"},{"issue":"9","key":"10674_CR26","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. Ann Oncol 32(9):1148\u20131156","journal-title":"Ann Oncol"},{"key":"10674_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2024","unstructured":"Bardia A, Modi S, Tolaney SM et al (2024) Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic HR+ HER2- breast cancer: primary results from TROPION-Breast01. J Clin Oncol 43:285\u2013296","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10674_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-138849","volume":"136","author":"SK Barta","year":"2020","unstructured":"Barta SK, Feldman TA, DeSimone JA et al (2020) A phase I trial assessing the feasibility of romidepsin combined with brentuximab vedotin for cutaneous T-cell lymphoma (abstract). Blood 136(Supplement 1):24\u201325","journal-title":"Blood"},{"issue":"Suppl","key":"10674_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e13130","volume":"41","author":"C Bieth","year":"2023","unstructured":"Bieth C (2023) Trastuzumab-deruxtecan in HER2-low metastatic\/unresectable breast cancer: real-life data in Parisian centers (abstract). J Clin Oncol 41(Suppl):e13130","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e13034","volume":"41","author":"DA Blotta","year":"2023","unstructured":"Blotta DA, Gomes JR, Moreira SBR et al (2023) Real-world outcomes of long-term efficacy of T-DM1 after discontinuation due to limiting toxicity in patients with HER2-positive metastatic breast cancer. J Clin Oncol 41(16_suppl):e13034-e","journal-title":"J Clin Oncol"},{"key":"10674_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101425","author":"G Buono","year":"2023","unstructured":"Buono G, Deleuze A, Klocker EV et al (2023) 237P real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101425","journal-title":"ESMO Open"},{"issue":"Suppl 5","key":"10674_CR32","doi-asserted-by":"publisher","first-page":"v715","DOI":"10.1093\/annonc\/mdz264.012","volume":"30","author":"E Calvo","year":"2019","unstructured":"Calvo E et al (2019) Phase I open-label study evaluating ABBV-181 and rovalpituzumab tesirine in patients with small cell lung cancer (abstract). Ann Oncol 30(Suppl 5):v715\u2013v716","journal-title":"Ann Oncol"},{"key":"10674_CR33","doi-asserted-by":"crossref","unstructured":"Camidge DR, Morgensztern D, Heist RS et al (2022) Phase I study of 2- or 3-week dosing of telisotuzumab vedotin monotherapy in patients with advanced non-small cell lung carcinoma. J Clin Oncol.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/34426443\/","DOI":"10.1158\/1078-0432.CCR-21-0765"},{"issue":"102\u2013103","key":"10674_CR34","first-page":"S201","volume":"6","author":"C Carlo-Stella","year":"2022","unstructured":"Carlo-Stella C, Ansell S, Zinzani PL et al (2022) Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma. HemaSphere 6(102\u2013103):S201","journal-title":"HemaSphere"},{"issue":"4","key":"10674_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00262-002-0343-x","volume":"52","author":"SY Chan","year":"2003","unstructured":"Chan SY, Gordon AN, Coleman RE et al (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother 52(4):243\u2013248","journal-title":"Cancer Immunol Immunother"},{"issue":"16_suppl","key":"10674_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e15008","volume":"42","author":"H-J Chen","year":"2024","unstructured":"Chen H-J, Wang S, Su R et al (2024) BC3195, a novel ADC targeting CDH3: preliminary results of a first-in-human phase I study in patients with advanced solid malignancies. J Clin Oncol 42(16_suppl):e15008-e","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR37","volume":"43","author":"J Chen","year":"2025","unstructured":"Chen J, Lin J, Zhu S, Zhang W, Wei Y (2025) Real-world effectiveness and safety of RC48-ADC combined with PD-1 inhibitors for patients with metastatic urothelial carcinoma: a retrospective multicenter study. J Clin Oncol 43(16_suppl):e16551-e","journal-title":"J Clin Oncol"},{"issue":"Suppl_1","key":"10674_CR38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1182\/blood.V130.Suppl_1.738.738","volume":"130","author":"RH Chen","year":"2017","unstructured":"Chen RH, Palmar JM, Herrera AF et al (2017) Phase II study of brentuximab vedotin plus ibrutinib for patients with relapsed\/refractory Hodgkin lymphoma. Blood 130(Suppl_1):738","journal-title":"Blood"},{"issue":"16_suppl","key":"10674_CR39","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1200\/JCO.2025.43.16_suppl.3026","volume":"43","author":"X Cheng","year":"2025","unstructured":"Cheng X, Song Z, Li N et al (2025) First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol 43(16_suppl):3026","journal-title":"J Clin Oncol"},{"issue":"22","key":"10674_CR40","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1182\/blood.V128.22.1148.1148","volume":"128","author":"AD Cohen","year":"2016","unstructured":"Cohen AD, Popat R, Trudel S et al (2016) First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-cell maturation antigen (BCMA) in patients with relapsed\/refractory multiple myeloma (MM): results from study BMA117159 part 1 dose escalation. Blood 128(22):1148","journal-title":"Blood"},{"issue":"16_suppl","key":"10674_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2025.43.16_suppl.105","volume":"43","author":"AJ Cooper","year":"2025","unstructured":"Cooper AJ, Chandana SR, Furqan M et al (2025) Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms. J Clin Oncol 43(16_suppl):105","journal-title":"J Clin Oncol"},{"key":"10674_CR42","unstructured":"Cortes J, DeAngelo D, Wang E et al (2017) Initial results from a first-in-human study of IMGN779, a CD33-targeting antibody-drug conjugate (ADC) with novel DNA alyklating activity, in patients with relapsed or refractory AML. EHA Libr.\u00a0https:\/\/library.ehaweb.org\/eha\/2017\/22nd\/181849\/jorge.cortes.initial.results.from.a.first-in-human.study.of.imgn779.a.html"},{"issue":"3","key":"10674_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10637-016-0343-x","volume":"34","author":"AL Coveler","year":"2016","unstructured":"Coveler AL, Ko AH, Catenacci DV et al (2016) A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs 34(3):319\u2013328","journal-title":"Invest New Drugs"},{"issue":"16_suppl","key":"10674_CR44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e15010","volume":"42","author":"J Coward","year":"2024","unstructured":"Coward J, Kichenadasse G, Park JJ et al (2024) Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol 42(16_suppl):e15010-e","journal-title":"J Clin Oncol"},{"issue":"36","key":"10674_CR45","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.19.00646","volume":"37","author":"DC Danila","year":"2019","unstructured":"Danila DC, Szmulewitz RZ, Vaishampayan U et al (2019) Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer. J Clin Oncol 37(36):3518\u201327","journal-title":"J Clin Oncol"},{"issue":"2","key":"10674_CR46","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/leu.2015.244","volume":"30","author":"N Daver","year":"2016","unstructured":"Daver N, Kantarjian H, Ravandi F et al (2016) A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30(2):268\u2013273","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10674_CR47","first-page":"2913","volume":"134","author":"N Daver","year":"2019","unstructured":"Daver N, Lane AA, Loghavi S et al (2019) IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed\/refractory acute leukemias and high-risk myelodysplastic syndromes. Blood 134(Suppl 1):2913","journal-title":"Blood"},{"issue":"Supplement 1","key":"10674_CR48","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2023-173413","volume":"142","author":"N Daver","year":"2023","unstructured":"Daver N, Montesinos P, Altman JK et al (2023) Pivekimab sunirine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia. Blood 142(Supplement 1):2906","journal-title":"Blood"},{"issue":"3","key":"10674_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","volume":"20","author":"JS de Bono","year":"2019","unstructured":"de Bono JS, Concin N, Hong DS et al (2019) Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol 20(3):383\u2013393","journal-title":"Lancet Oncol"},{"key":"10674_CR50","doi-asserted-by":"publisher","first-page":"S805","DOI":"10.1016\/j.annonc.2024.08.1314","volume":"35","author":"M De Miguel","year":"2024","unstructured":"De Miguel M, yamamoto N, Raimbourg J et al (2024) 1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): results from a phase I study. Ann Oncol 35:S805\u2013S6","journal-title":"Ann Oncol"},{"issue":"13","key":"10674_CR51","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","volume":"27","author":"GD Demetri","year":"2021","unstructured":"Demetri GD, Luke JJ, Hollebecque A, Powderly JD (2021) First-in-human phase I study of ABBV-085, an antibody\u2013drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors. Clin Cancer Res 27(13):3556\u20133564","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10674_CR52","volume":"31","author":"L Dho","year":"2024","unstructured":"Dho L, Maire A, Levenbruck C, Coussirou J, Zerbib D, De Crozals F (2024) 4CPS-180\u2005sacituzumab-govitecan in metastatic triple-negative breast cancer: comparison of our data to the ascent trial after 2 years of experience. Eur J Hosp Pharm 31(Suppl 1):A138","journal-title":"Eur J Hosp Pharm"},{"issue":"Supplement 1","key":"10674_CR53","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2022-157720","volume":"140","author":"C Diefenbach","year":"2022","unstructured":"Diefenbach C, Abrisqueta P, Gonz\u00e1lez-Barca E et al (2022) A phase Ib\/II study of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed\/refractory follicular lymphoma: final analysis with PFS update. Blood 140(Supplement 1):2286\u20132288","journal-title":"Blood"},{"key":"10674_CR54","doi-asserted-by":"crossref","unstructured":"Doi T, Patel MR, Koyama T et al (2023) Ifinatamab deruxtecan (I\u2011DXd; DS\u20117300) in patients with advanced solid tumors: updated clinical and biomarker results from a Phase I\/II study. Ann Oncol 34(Suppl 7): S481\u2011S2","DOI":"10.1016\/j.annonc.2023.09.1876"},{"key":"10674_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/hon.73_2881","author":"E Domingo Domenech","year":"2021","unstructured":"Domingo Domenech E, Sancho Cia JM, Gonzalez Barca E et al (2021) Brentuximab vedotin plus chp as first-line treatment in CD30 + peripheral T-cell lymphomas: real life experience from a single institution in Spain. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.73_2881","journal-title":"Hematol Oncol"},{"issue":"32","key":"10674_CR56","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic M, Pinter-Brown LC, Foss FM et al (2015) Phase II study of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 33(32):3759\u20133765","journal-title":"J Clin Oncol"},{"issue":"5_Supplement","key":"10674_CR57","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-PD18-10","volume":"83","author":"S Escriv\u00e1-de-Romani","year":"2023","unstructured":"Escriv\u00e1-de-Romani S, Alba E, Rodr\u00edguez-Lescure \u00c1 et al (2023) Abstract PD18-10: treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant. Cancer Res 83(5_Supplement):PD18-0-PD-0","journal-title":"Cancer Res"},{"issue":"11","key":"10674_CR58","first-page":"3056","volume":"18","author":"MA Fanale","year":"2012","unstructured":"Fanale MA, Younes A, Bartlett NL et al (2012) Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Clin Cancer Res 18(11):3056\u20133063","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10674_CR59","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/blood.V126.23.4414.4414","volume":"126","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres A, Assi R, Lugtenburg P et al (2015) Brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma: subset report of E4402 (n = 102) North American study. Blood 126(23):4414","journal-title":"Blood"},{"issue":"17_suppl","key":"10674_CR60","volume":"43","author":"SA Funt","year":"2025","unstructured":"Funt SA, Pal SK, Taylor MM, Cosgriff TM, McDermott RS, Galsky MD (2025) Safety and activity of enfortumab vedotin in advanced urothelial carcinoma: a phase I\/II multitumor study (EV\u2011302 expansion). J Clin Oncol 43(17_suppl):4508","journal-title":"J Clin Oncol"},{"issue":"13","key":"10674_CR61","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO.2007.15.0532","volume":"26","author":"MD Galsky","year":"2008","unstructured":"Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26(13):2147\u20132154","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR62","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2025.43.16_suppl.3029","volume":"43","author":"S Gao","year":"2025","unstructured":"Gao S, Chen J, Lu C et al (2025) A first-in-human clinical study of 9MW2921, a novel TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol 43(16_suppl):3029","journal-title":"J Clin Oncol"},{"issue":"7","key":"10674_CR63","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/ijc.32154","volume":"145","author":"I Garrido-Laguna","year":"2019","unstructured":"Garrido-Laguna I, Krop I, Burris HA 3rd et al (2019) First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer 145(7):1798\u20131808","journal-title":"Int J Cancer"},{"issue":"24","key":"10674_CR64","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1002\/cncr.33195","volume":"126","author":"JI Geller","year":"2020","unstructured":"Geller JI, Pressey JG, Smith MA et al (2020) ADVL1522: a phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children\u2019s Oncology Group study. Cancer 126(24):5303\u20135310","journal-title":"Cancer"},{"issue":"18","key":"10674_CR65","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-23-0640","volume":"29","author":"S George","year":"2023","unstructured":"George S, Heinrich MC, Somaiah N et al (2023) A phase I, multicenter, open-label, first-in-human study of DS-6157a in patients with advanced gastrointestinal stromal tumor. Clin Cancer Res 29(18):3659\u20133667","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10674_CR66","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/1078-0432.CCR-18-3965","volume":"26","author":"DE Gerber","year":"2020","unstructured":"Gerber DE, Infante JR, Gordon MS et al (2020) Phase Ia study of anti-NaPi2b antibody\u2013drug conjugate lifastuzumab vedotin DNIB0600A in patients with non\u2013small cell lung cancer and platinum-resistant ovarian cancer. Clin Cancer Res 26(2):364\u2013372","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10674_CR67","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","volume":"120","author":"AK Gopal","year":"2012","unstructured":"Gopal AK, Ramchandren R, O\u2019Connor OA et al (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120(3):560\u2013568","journal-title":"Blood"},{"issue":"19","key":"10674_CR68","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C et al (2021) Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood 137(19):2634\u20132645","journal-title":"Blood"},{"issue":"3","key":"10674_CR69","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ygyno.2020.05.038","volume":"158","author":"E Hamilton","year":"2020","unstructured":"Hamilton E, O\u2019Malley DM, O\u2019Cearbhaill R et al (2020) Tamrintamab pamozirine (SC-003) in patients with platinum-resistant\/refractory ovarian cancer: findings of a phase 1 study. Gynecol Oncol 158(3):640\u2013645","journal-title":"Gynecol Oncol"},{"key":"#cr-split#-10674_CR70.1","unstructured":"Hamilton EP, Dosunmu O, Shastry M et al (2023) A phase II study of patritumab deruxtecan (U3-1402"},{"key":"#cr-split#-10674_CR70.2","doi-asserted-by":"crossref","unstructured":"HER3-DXd) in metastatic breast cancer: clinical activity and safety (ASCO 2023 abstract). J Clin Oncol 41(16_suppl): 1004","DOI":"10.1200\/JCO.2023.41.16_suppl.1004"},{"issue":"16_suppl","key":"10674_CR71","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/JCO.2025.43.16_suppl.3009","volume":"43","author":"EP Hamilton","year":"2025","unstructured":"Hamilton EP, Han HS, Kalinsky K et al (2025) Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate. J Clin Oncol 43(16_suppl):3009","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR72","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2022.40.16_suppl.3002","volume":"40","author":"EP Hamilton","year":"2022","unstructured":"Hamilton EP, Jauhari S, Moore KN et al (2022) Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC). J Clin Oncol 40(16_suppl):3002","journal-title":"J Clin Oncol"},{"key":"10674_CR73","doi-asserted-by":"publisher","first-page":"A343","DOI":"10.1136\/ijgc-2024-ESGO.671","volume":"34","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Papadopoulos KP, Barve M et al (2024) 559\u2005Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC). Int J Gynecol Cancer 34:A343","journal-title":"Int J Gynecol Cancer"},{"key":"10674_CR74","doi-asserted-by":"publisher","first-page":"v711","DOI":"10.1093\/annonc\/mdz264.003","volume":"30","author":"C Hann","year":"2019","unstructured":"Hann C, Burns T, Dowlati A et al (2019) A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC). Ann Oncol 30:v711\u2013v712","journal-title":"Ann Oncol"},{"issue":"12","key":"10674_CR75","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","volume":"130","author":"D Hanna","year":"2024","unstructured":"Hanna D, Merrick S, Ghose A et al (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer 130(12):1916\u20131920","journal-title":"Br J Cancer"},{"issue":"16","key":"10674_CR76","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.19.02085","volume":"38","author":"R Hassan","year":"2020","unstructured":"Hassan R, Blumenschein GR Jr., Moore KN et al (2020) First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol 38(16):1824\u20131835","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10674_CR77","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1182\/blood-2024-203008","volume":"144","author":"Z He","year":"2024","unstructured":"He Z, Zhu H, Wei C et al (2024) Multicenter real-world use of polatuzumab vedotin in diffuse large B-cell lymphoma(DLBCL) of frontline and relapse\/refractory settings in China. Blood 144(Supplement 1):6504","journal-title":"Blood"},{"issue":"16_suppl","key":"10674_CR78","doi-asserted-by":"publisher","first-page":"8613","DOI":"10.1200\/JCO.2025.43.16_suppl.8613","volume":"43","author":"R Heist","year":"2025","unstructured":"Heist R, Shum E, Garcia E et al (2025) MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: updated dose escalation results in the phase 1 KisMET-01 study. J Clin Oncol 43(16_suppl):8613","journal-title":"J Clin Oncol"},{"key":"10674_CR79","doi-asserted-by":"publisher","first-page":"S1670","DOI":"10.1016\/j.annonc.2023.10.594","volume":"34","author":"H Horinouchi","year":"2023","unstructured":"Horinouchi H, Cho BC, Camidge DR et al (2023) 515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): final efficacy and safety updates. Ann Oncol 34:S1670","journal-title":"Ann Oncol"},{"issue":"5","key":"10674_CR80","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","volume":"36","author":"H Horinouchi","year":"2025","unstructured":"Horinouchi H, Cho BC, Camidge DR et al (2025) Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol 36(5):583\u2013591","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10674_CR81","first-page":"928","volume":"132","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Hamadani M, Collins GP et al (2018) Phase I study of camidanlumab tesirine (ADCT-301) in relapsed\/refractory lymphomas: safety and preliminary activity. Blood 132(Suppl 1):928","journal-title":"Blood"},{"key":"10674_CR82","doi-asserted-by":"crossref","unstructured":"Jain N, Maiti A, Ravandi F et al (2020) Inotuzumab ozogamicin plus bosutinib in R\/R Ph+ ALL or CML in lymphoid blast phase (CML LBP). EHA Libr\u00a0(294315): EP396","DOI":"10.1200\/JCO.2020.38.15_suppl.7512"},{"issue":"3","key":"10674_CR83","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/bloodadvances.2019000767","volume":"4","author":"N Jain","year":"2020","unstructured":"Jain N, Stock W, Zeidan A et al (2020) Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood Adv 4(3):449\u2013457","journal-title":"Blood Adv"},{"issue":"4","key":"10674_CR84","volume":"4","author":"M Jebbink","year":"2023","unstructured":"Jebbink M, de Langen AJ, Monkhorst K et al (2023) Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC. JTO Clin Res Rep 4(4):100481","journal-title":"JTO Clin Res Rep"},{"issue":"16_suppl","key":"10674_CR85","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/JCO.2024.42.16_suppl.5550","volume":"42","author":"H Jia","year":"2024","unstructured":"Jia H, Zhang S, Sun Y et al (2024) Phase 1 study of BAT8006, a folate receptor \u03b1 antibody drug conjugate with strong bystander effect, in subjects with advanced solid tumors. J Clin Oncol 42(16_suppl):5550","journal-title":"J Clin Oncol"},{"key":"10674_CR86","doi-asserted-by":"crossref","unstructured":"Jiang L, Song Z, Gong Y et al (2024) A phase 1 study of BAT8007, an anti-nectin-4 monoclonal antibody-exatecan conjugate, in patients with advanced solid tumors. J Clin Oncol\u00a042(16_suppl): e16567-e","DOI":"10.1200\/JCO.2024.42.16_suppl.e16567"},{"issue":"16_suppl","key":"10674_CR87","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1200\/JCO.2022.40.16_suppl.1102","volume":"40","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Sun T, Wang X et al (2022) A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer. J Clin Oncol 40(16_suppl):1102","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10674_CR88","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1200\/JCO.2020.38.15_suppl.3502","volume":"38","author":"ML Johnson","year":"2020","unstructured":"Johnson ML, El-Khoueiry AB, Hafez N et al (2020) CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. J Clin Oncol 38(15_suppl):3502","journal-title":"J Clin Oncol"},{"issue":"9","key":"10674_CR89","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","volume":"16","author":"ML Johnson","year":"2021","unstructured":"Johnson ML, Zvirbule Z, Laktionov K et al (2021) Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. J Thorac Oncol 16(9):1570\u20131581","journal-title":"J Thorac Oncol"},{"key":"10674_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.557","volume":"35","author":"S Kadowaki","year":"2024","unstructured":"Kadowaki S, Yoshino T, Yamazaki K et al (2024) MO25-2 phase 1 study of tusamitamab ravtansine every 2 weeks with loading dose in Japanese patients with advanced solid tumors. Ann Oncol 35:S1340","journal-title":"Ann Oncol"},{"issue":"8","key":"10674_CR91","first-page":"455","volume":"16","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, O\u2019Brien S, Thomas DA, Faderl S, Garcia-Manero G (2016) A phase II study of coltuximab ravtansine (SAR3419) monotherapy in adults with relapsed or refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 16(8):455\u2013461","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"10674_CR92","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1182\/blood.V128.22.4486.4486","volume":"128","author":"KR Kelly","year":"2016","unstructured":"Kelly KR, Siegel D, Vij R, Mikhael J (2016) Indatuximab ravtansine (BT062) in combination with lenalidomide or pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma. Blood 128(22):4486","journal-title":"Blood"},{"key":"10674_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/hon.123_2880","author":"N Khan","year":"2021","unstructured":"Khan N, Noor S, Geller S et al (2021) A phase II trial of reduced dose brentuximab vedotin for cutaneous T-cell lymphomas. Hematol Oncol. https:\/\/doi.org\/10.1002\/hon.123_2880","journal-title":"Hematol Oncol"},{"issue":"2","key":"10674_CR94","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","volume":"91","author":"RD Kim","year":"2023","unstructured":"Kim RD, Ryan DP, Parikh A, Leal AD (2023) A phase I first-in-human study of TAK-164, a GCC-targeting ADC, in patients with advanced gastrointestinal cancers. Cancer Chemother Pharmacol 91(2):291\u2013300","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10674_CR95","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/onco.13628","volume":"26","author":"CK Kollmannsberger","year":"2021","unstructured":"Kollmannsberger CK, Choueiri TK, Heng DYC, George S (2021) Randomized phase II study of AGS-16C3F versus axitinib in previously treated metastatic renal cell carcinoma. Oncologist 26(3):182\u2013190","journal-title":"Oncologist"},{"key":"10674_CR96","doi-asserted-by":"publisher","first-page":"A56","DOI":"10.1136\/ijgc-2024-IGCS.73","volume":"34","author":"G Konecny","year":"2024","unstructured":"Konecny G, Hendrickson AW, Winterhoff B et al (2024) PR031\/#1199 Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1\u201323, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors. Int J Gynecol Cancer 34:A56","journal-title":"Int J Gynecol Cancer"},{"issue":"8_Supplement","key":"10674_CR97","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT185","volume":"83","author":"N Kotecki","year":"2023","unstructured":"Kotecki N, van Herpen CML, Curigliano C et al (2023) Abstract CT185: first in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521. Cancer Res 83(8_Supplement):CT185-CT","journal-title":"Cancer Res"},{"issue":"12","key":"10674_CR98","first-page":"2618","volume":"82","author":"IE Krop","year":"2022","unstructured":"Krop IE, Tolaney SM, Rugo HS, Cortes J (2022) Datopotamab deruxtecan (Dato-DXd) in metastatic triple-negative breast cancer: translational biomarker analysis from TROPION-PanTumor01. Cancer Res 82(12):2618\u20132628","journal-title":"Cancer Res"},{"issue":"10S","key":"10674_CR99","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000950748.13716.b3","volume":"118","author":"A Kuang","year":"2023","unstructured":"Kuang A, Shah JS, Mittal N et al (2023) S277\u2003gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy. Official journal of the American College of Gastroenterology | ACG 118(10S):S203","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"issue":"Supplement 1","key":"10674_CR100","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/blood-2023-189005","volume":"142","author":"M Lasica","year":"2023","unstructured":"Lasica M, Spencer A, Horvath N et al (2023) A phase I\/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: planned interim analysis of safety and efficacy. Amarc 19-02 Belacard Study. Blood 142(Supplement 1):2012","journal-title":"Blood"},{"issue":"6","key":"10674_CR101","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s10637-020-00960-z","volume":"38","author":"C Lemech","year":"2020","unstructured":"Lemech C, Woodward N, Chan N et al (2020) A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Invest New Drugs 38(6):1815\u20131825","journal-title":"Invest New Drugs"},{"issue":"8_Supplement","key":"10674_CR102","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT178","volume":"83","author":"C Lemech","year":"2023","unstructured":"Lemech C, Zhou C, Zhan X et al (2023) Abstract CT178: GQ1001: a next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, phase Ia study. Cancer Res 83(8_Supplement):CT178-CT","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10674_CR103","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1200\/JCO.2025.43.16_suppl.4018","volume":"43","author":"RW Lentz","year":"2025","unstructured":"Lentz RW, Ng MCH, Yong W-P et al (2025) Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study. J Clin Oncol 43(16_suppl):4018","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10674_CR104","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1182\/blood-2024-204718","volume":"144","author":"Y Li","year":"2024","unstructured":"Li Y, Zeng R, Xia C et al (2024) Brentuximab vedotin-based treatment in patients with CD30-positive lymphoma: a retrospective analysis. Blood 144(Supplement 1):6465","journal-title":"Blood"},{"issue":"16_suppl","key":"10674_CR105","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.2025.43.16_suppl.3037","volume":"43","author":"R Lin","year":"2025","unstructured":"Lin R, Hao J, Su L et al (2025) First-in-human trial of SYS6010 combined with SYH2051 in patients with advanced gastrointestinal tumors. J Clin Oncol 43(16_suppl):3037","journal-title":"J Clin Oncol"},{"issue":"3","key":"10674_CR106","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2021.09.023","volume":"163","author":"J Liu","year":"2021","unstructured":"Liu J, Burris H, Wang JS et al (2021) An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol 163(3):473\u201380","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10674_CR107","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","volume":"27","author":"JF Liu","year":"2016","unstructured":"Liu JF, Moore KN, Birrer MJ et al (2016) Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol 27(11):2124\u201330","journal-title":"Ann Oncol"},{"key":"10674_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.311","volume":"35","author":"JJ Liu","year":"2024","unstructured":"Liu JJ, Yu X, Zhang J et al (2024) 396MO anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric\/gastro-esophageal junction adenocarcinoma (G\/GEJ AC): a phase I study. Ann Oncol 35:S160","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10674_CR109","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1200\/JCO.2025.43.16_suppl.4590","volume":"43","author":"S Liu","year":"2025","unstructured":"Liu S, Miao H, Xue S et al (2025) Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): a single-arm, prospective, phase 2 clinical trial. J Clin Oncol 43(16_suppl):4590","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR110","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2024.42.16_suppl.3031","volume":"42","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang J, Shen L et al (2024) Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: a phase I\/II clinical study. J Clin Oncol 42(16_suppl):3031","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10674_CR111","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1182\/blood-2024-202402","volume":"144","author":"Z Liu","year":"2024","unstructured":"Liu Z, Zheng Y, Liu X et al (2024) Real-world results of brentuximab vedotin containing regimens in CD30 positive lymphoma: a single-center retrospective study. Blood 144(Supplement 1):6529","journal-title":"Blood"},{"issue":"10","key":"10674_CR112","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","volume":"5","author":"F Locatelli","year":"2018","unstructured":"Locatelli F, Mauz-K\u00f6rholz C, Neville K et al (2018) Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and systemic anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 trial. The Lancet Haematology 5(10):e450\u2013e459","journal-title":"The Lancet Haematology"},{"key":"10674_CR113","first-page":"11","volume":"167","author":"S Loibl","year":"2022","unstructured":"Loibl S, Bachelot T, Pivot X et al (2022) Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan in pretreated metastatic triple-negative breast cancer. Eur J Cancer 167:11\u201320","journal-title":"Eur J Cancer"},{"issue":"16_suppl","key":"10674_CR114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e15007","volume":"42","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang Q, Meng X et al (2024) Results of a phase 1\/2 study of MHB036C: a potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors. J Clin Oncol 42(16_suppl):e15007-e","journal-title":"J Clin Oncol"},{"issue":"8_Supplement_2","key":"10674_CR115","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT008","volume":"85","author":"S Lu","year":"2025","unstructured":"Lu S, Zhou Z, Li Z-M et al (2025) Abstract CT008: first-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors. Cancer Res 85(8_Supplement_2):CT008-CT","journal-title":"Cancer Res"},{"key":"10674_CR116","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1016\/j.annonc.2024.08.063","volume":"35","author":"Z Lu","year":"2024","unstructured":"Lu Z, Chang L, Zhou J et al (2024) 54P BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic biliary tract carcinoma (BTC). Ann Oncol 35:S233","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10674_CR117","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2025.43.4_suppl.456","volume":"43","author":"J Ma","year":"2025","unstructured":"Ma J, Cao D, Zhao Q et al (2025) Safety and preliminary efficacy of ATG-022 in patients with advanced\/metastatic gastric cancer (CLINCH). J Clin Oncol 43(4_suppl):456","journal-title":"J Clin Oncol"},{"issue":"16","key":"10674_CR118","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-20-3757","volume":"27","author":"ML Maitland","year":"2021","unstructured":"Maitland ML, Sachdev JC, Sharma MR et al (2021) First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody\u2013drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors. Clin Cancer Res 27(16):4511\u20134520","journal-title":"Clin Cancer Res"},{"issue":"5_Supplement","key":"10674_CR119","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-P4-07-65","volume":"83","author":"F Marm\u00e9","year":"2023","unstructured":"Marm\u00e9 F, Bardia A, Rugo H et al (2023) Abstract P4-07-65: effect of sacituzumab govitecan vs chemotherapy in HR+\/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial. Cancer Res 83(5_Supplement):P4-07-65-P4-07-65","journal-title":"Cancer Res"},{"key":"10674_CR120","doi-asserted-by":"crossref","unstructured":"Mascolo A, Scavone C, Bertini M et al (2020) Safety of anticancer agents used in children: a focus on their off-label use through data from the spontaneous reporting system. Front Pharmacol\u00a0 Volume 11-2020.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/32457620\/","DOI":"10.3389\/fphar.2020.00621"},{"issue":"4","key":"10674_CR121","first-page":"714","volume":"37","author":"C Massard","year":"2019","unstructured":"Massard C, Ghiringhelli F, Dumez H et al (2019) First-in-human study of AMG 172 in metastatic renal cell carcinoma (NCT01497821). Invest New Drugs 37(4):714\u2013722","journal-title":"Invest New Drugs"},{"issue":"6","key":"10674_CR122","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s10637-020-00945-y","volume":"38","author":"BA-O McGregor","year":"2020","unstructured":"McGregor BA-O, Gordon MA-O, Flippot RA-O et al (2020) Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs 38(6):1807\u201314","journal-title":"Invest New Drugs"},{"issue":"8","key":"10674_CR123","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clml.2024.03.013","volume":"24","author":"M Mei","year":"2024","unstructured":"Mei M, Tsai NC, Palmer J et al (2024) Brentuximab vedotin plus ibrutinib in relapsed and refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 24(8):537\u2013542","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10674_CR124","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F, Alhalabi O, Lisberg A et al (2025) Datopotamab deruxtecan (Dato-DXd) in locally advanced\/metastatic urothelial cancer: updated results from the phase 1 TROPIONPanTumor01 study. J Clin Oncol\u00a043(5_suppl): 663-","DOI":"10.1200\/JCO.2025.43.5_suppl.663"},{"issue":"Suppl 6","key":"10674_CR125","first-page":"1120","volume":"35","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Piha-Paul S, Bauer TM et al (2024) Phase I study of puxitatug samrotecan (P-Sam; AZD8205): early results across multiple solid tumors. Ann Oncol 35(Suppl 6):1120","journal-title":"Ann Oncol"},{"key":"10674_CR126","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam FA-O, Gutierrez MA-O, Sanz-Garcia EA-O et al (2025) Phase 2 study of zilovertamab vedotin in participants with metastatic solid tumors. Cancer Res Commun 5(9): 1664\u201373","DOI":"10.1158\/2767-9764.CRC-25-0019"},{"issue":"6","key":"10674_CR127","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","volume":"8","author":"L-O Metheny","year":"2024","unstructured":"Metheny L-O, Sobecks R, Cho C et al (2024) A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv 8(6):1384\u201391","journal-title":"Blood Adv"},{"issue":"5","key":"10674_CR128","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-24-2523","volume":"31","author":"L Michel","year":"2025","unstructured":"Michel L, Jimeno A, Sukari A et al (2025) Sacituzumab govitecan in patients with relapsed\/refractory advanced head and neck squamous cell carcinoma: results from the phase II TROPiCS-03 basket study. Clin Cancer Res 31(5):832\u2013838","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10674_CR129","first-page":"2226","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, O\u2019Malley DM, Matulonis UA et al (2017) A phase I study of mirvetuximab soravtansine (IMGN853) in patients with FR\u03b1-positive recurrent ovarian cancer. J Clin Oncol 35(19):2226\u20132234","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR130","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2023.41.16_suppl.3023","volume":"41","author":"KN Moore","year":"2023","unstructured":"Moore KN, Sabanathan D, Du Y et al (2023) Safety and efficacy of DB-1303 in patients with advanced\/metastatic solid tumors: a multicenter, open-label, first-in-human, phase 1\/2a study. J Clin Oncol 41(16_suppl):3023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR131","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2023.41.16_suppl.3002","volume":"41","author":"D Morgensztern","year":"2023","unstructured":"Morgensztern D, Ready NE, Johnson ML et al (2023) First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate, in patients with small cell lung cancer. J Clin Oncol 41(16_suppl):3002","journal-title":"J Clin Oncol"},{"key":"10674_CR132","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1182\/blood-2023-184898","volume":"142","author":"B Munayirji","year":"2023","unstructured":"Munayirji B, Khan N, Myskowski P et al (2023) Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability. Blood 142:1702","journal-title":"Blood"},{"key":"10674_CR133","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz343.033","volume":"30","author":"H Murakami","year":"2019","unstructured":"Murakami H, Wakuda K, Kenmotsu H et al (2019) Preliminary results of safety and PK of telisotuzumab vedotin (T) in Japanese patients with advanced solid tumors. Ann Oncol 30:vi125","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10674_CR134","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5513","volume":"40","author":"S Nishio","year":"2022","unstructured":"Nishio S, Yunokawa M, Matsumoto K et al (2022) Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): results from the expansion part of a phase 1 trial. J Clin Oncol 40(16_suppl):5513","journal-title":"J Clin Oncol"},{"issue":"4","key":"10674_CR135","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41408-022-00653-1","volume":"12","author":"AK Nooka","year":"2022","unstructured":"Nooka AK, Kaufman JL, Rodriguez C et al (2022) Daratumumab plus lenalidomide\/bortezomib\/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J 12(4):63","journal-title":"Blood Cancer J"},{"key":"10674_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.674","volume":"35","author":"M Oliva","year":"2024","unstructured":"Oliva M, Ochsenreither S, Le Tourneau C et al (2024) 607o interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors. Ann Oncol 35:S486","journal-title":"Ann Oncol"},{"key":"10674_CR137","doi-asserted-by":"publisher","first-page":"S1639","DOI":"10.1016\/j.annonc.2023.10.540","volume":"34","author":"A Ooki","year":"2023","unstructured":"Ooki A, Aoyama T, Oba K et al (2023) 454P a multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced\/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study. Ann Oncol 34:S1639\u2013S40","journal-title":"Ann Oncol"},{"key":"10674_CR138","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw379.42","volume":"27","author":"PA Ott","year":"2016","unstructured":"Ott PA, Pavlick AC, Johnson DB et al (2016) A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. Ann Oncol 27:vi393","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10674_CR139","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.2024.42.4_suppl.608","volume":"42","author":"M Parikh","year":"2024","unstructured":"Parikh M, Boateng F, Eng S et al (2024) A retrospective cohort study to monitor real-world safety in patients with locally advanced or metastatic urothelial carcinoma (LA\/mUC) treated with sacituzumab govitecan (SG) in the United States. J Clin Oncol 42(4_suppl):608","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10674_CR140","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2025.43.5_suppl.709","volume":"43","author":"M Parikh","year":"2025","unstructured":"Parikh M, McMahon P, Eng S et al (2025) Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan (SG)-treated patients (pts) with locally advanced\/metastatic urothelial cancer (la\/mUC). J Clin Oncol 43(5_suppl):709","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR141","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2024.42.16_suppl.3038","volume":"42","author":"JJ Park","year":"2024","unstructured":"Park JJ, Gao B, Beecroft C et al (2024) Safety and efficacy of JSKN003 in patients with advanced\/metastatic solid tumors: a first-in-human, dose-escalation, multicenter, open-label, phase I study. J Clin Oncol 42(16_suppl):3038","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10674_CR142","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1182\/blood-2024-193442","volume":"144","author":"AA Patel","year":"2024","unstructured":"Patel AA, Duvall AS, Saygin C et al (2024) Interim results of a phase II study investigating dasatinib and inotuzumab ozogamicin-based induction for newly-diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Blood 144(Supplement 1):1432","journal-title":"Blood"},{"key":"10674_CR143","doi-asserted-by":"publisher","first-page":"S488","DOI":"10.1016\/j.annonc.2024.08.677","volume":"35","author":"MR Patel","year":"2024","unstructured":"Patel MR, Hamilton EP, Piha-Paul SA et al (2024) 610O preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6. Ann Oncol 35:S488\u2013S9","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"10674_CR144","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1182\/blood-2021-146681","volume":"138","author":"N Pemmaraju","year":"2021","unstructured":"Pemmaraju N, Marconi G, Todisco E et al (2021) A study of IMGN632, a novel CD123-targeting antibody-drug conjugate, for patients with frontline and relapsed\/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood 138(Supplement 1):4429","journal-title":"Blood"},{"issue":"16_suppl","key":"10674_CR145","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3033","volume":"43","author":"CA Perez","year":"2025","unstructured":"Perez CA, Mileshkin LR, D\u2019Alonzo S et al (2025) First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: preliminary results of the dose-escalation phase. J Clin Oncol 43(16_suppl):3033","journal-title":"J Clin Oncol"},{"issue":"1","key":"10674_CR146","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1158\/1078-0432.CCR-22-3627","volume":"30","author":"DP Petrylak","year":"2024","unstructured":"Petrylak DP, Eigl BJ, George S et al (2024) Phase I dose-escalation study of the safety and pharmacokinetics of AGS15E monotherapy in patients with metastatic urothelial carcinoma. Clin Cancer Res 30(1):63\u201373","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10674_CR147","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","volume":"37","author":"T Phillips","year":"2019","unstructured":"Phillips T, Barr PM, Park SI et al (2019) A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs 37(2):297\u2013306","journal-title":"Invest New Drugs"},{"key":"10674_CR148","doi-asserted-by":"publisher","first-page":"S357","DOI":"10.1016\/j.annonc.2024.08.288","volume":"35","author":"B Pistilli","year":"2024","unstructured":"Pistilli B, Pierotti L, Lacroix-Triki M et al (2024) 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+\/HER2- advanced breast cancer (ABC). Ann Oncol 35:S357","journal-title":"Ann Oncol"},{"key":"10674_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101332","author":"F Poggio","year":"2023","unstructured":"Poggio F, Tagliamento M, Favero D et al (2023) 108P safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study). ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101332","journal-title":"ESMO Open"},{"issue":"8","key":"10674_CR150","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","volume":"31","author":"M Preusser","year":"2025","unstructured":"Preusser M, Garde-Noguera J, Garc\u00eda-Mosquera JJ et al (2025) Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. Nat Med 31(8):2797\u20132805","journal-title":"Nat Med"},{"issue":"15","key":"10674_CR151","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1158\/1078-0432.CCR-21-3078","volume":"28","author":"M Radovich","year":"2022","unstructured":"Radovich M, Solzak JP, Wang CJ et al (2022) Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer. Clin Cancer Res 28(15):3235\u201341","journal-title":"Clin Cancer Res"},{"key":"10674_CR152","doi-asserted-by":"crossref","unstructured":"Ramalingam S, Lopez J, Mau-Sorensen M et al (2019) OA02.05 first-in-human phase 1\/2 trial of anti-AXL antibody–drug conjugate (ADC) enapotamab vedotin (EnaV) in advanced NSCLC. J Thorac Oncol\u00a014(10): S209","DOI":"10.1016\/j.jtho.2019.08.414"},{"issue":"22","key":"10674_CR153","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1182\/blood.V128.22.4146.4146","volume":"128","author":"R Ramchandren","year":"2016","unstructured":"Ramchandren R, Mulroney CM, Patel MR, Sportelli P, Miskin HP, Chen RW (2016) A phase I trial of TGR-1202, a next generation once-daily PI3K\u03b4 inhibitor, in combination with brentuximab vedotin, in patients with relapsed\/refractory Hodgkins lymphoma. Blood 128(22):4146","journal-title":"Blood"},{"key":"10674_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105360","author":"Y Ren","year":"2025","unstructured":"Ren Y, Liao N, Liu N et al (2025) 15eP an observational study on the efficacy and safety of TROP2-targeted antibody-drug conjugates as a neoadjuvant therapy for early-stage HER2-negative breast cancer. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105360","journal-title":"ESMO Open"},{"key":"10674_CR155","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ygyno.2020.06.109","volume":"159","author":"DL Richardson","year":"2020","unstructured":"Richardson DL, Hamilton E, Tolcher A et al (2020) A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: a summary of dose escalation. Gynecol Oncol 159:52","journal-title":"Gynecol Oncol"},{"issue":"Supplement 1","key":"10674_CR156","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2024-199542","volume":"144","author":"J Richter","year":"2024","unstructured":"Richter J, Thomas SK, Krishnan AY et al (2024) Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. Blood 144(Supplement 1):1021","journal-title":"Blood"},{"key":"10674_CR157","doi-asserted-by":"publisher","first-page":"S585","DOI":"10.1016\/j.annonc.2021.08.1036","volume":"32","author":"J Rodon","year":"2021","unstructured":"Rodon J, Li J, Xue J et al (2021) 514o an open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors. Ann Oncol 32:S585","journal-title":"Ann Oncol"},{"key":"10674_CR158","doi-asserted-by":"crossref","unstructured":"Rodriguez Rivera II, Hafez N, Tolcher AW et al (2023) CBX-12\u2013101: a first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors. J Clin Oncol\u00a041(16_suppl): 3087-","DOI":"10.1200\/JCO.2023.41.16_suppl.3087"},{"issue":"1","key":"10674_CR159","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10637-019-00754-y","volume":"38","author":"LS Rosen","year":"2020","unstructured":"Rosen LS, Wesolowski R, Baffa R et al (2020) A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody\u2013drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs 38(1):120\u2013130","journal-title":"Invest New Drugs"},{"issue":"10","key":"10674_CR160","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J, Sridhar SS, Zhang J et al (2020) EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4\u2013positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 38(10):1041\u20131049","journal-title":"J Clin Oncol"},{"key":"10674_CR161","doi-asserted-by":"publisher","first-page":"S759","DOI":"10.1016\/j.annonc.2023.09.2352","volume":"34","author":"JK Rotow","year":"2023","unstructured":"Rotow JK, Waqar SN, Papadopoulos KP et al (2023) 1318MO first-in-human study of ABBV-637, an EGFR-targeting BCL-XL\u2013inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed\/refractory, EGFR-mutated non-small cell lung cancer (NSCLC). Ann Oncol 34:S759","journal-title":"Ann Oncol"},{"key":"10674_CR162","doi-asserted-by":"crossref","unstructured":"Ruan D-Y, Liu F-R, Wei X-L et al (2025) Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. The Lancet Oncol 26(2): 227\u201338","DOI":"10.1016\/S1470-2045(24)00636-3"},{"issue":"3","key":"10674_CR163","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10637-019-00832-1","volume":"38","author":"S Sandhu","year":"2020","unstructured":"Sandhu S, McNeil CM, LoRusso P et al (2020) Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Invest New Drugs 38(3):844\u2013854","journal-title":"Invest New Drugs"},{"issue":"Supplement 1","key":"10674_CR164","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1182\/blood-2023-177908","volume":"142","author":"F Schjesvold","year":"2023","unstructured":"Schjesvold F, Spencer A, Cohen YC et al (2023) Initial results from a phase 1 dose-escalation study of WVT078, a BCMA\u00d7CD3 bispecific antibody, in combination with WHG626, a gamma-secretase (GS) inhibitor, in patients with relapsed and\/or refractory multiple myeloma. Blood 142(Supplement 1):4752","journal-title":"Blood"},{"issue":"10","key":"10674_CR165","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1159\/000518549","volume":"44","author":"P Sch\u00f6ffski","year":"2021","unstructured":"Sch\u00f6ffski P, Concin N, Suarez C et al (2021) A phase 1 study of a CDH6-targeting antibody-drug conjugate in patients with advanced solid tumors with evaluation of inflammatory and neurological adverse events. Oncology Research and Treatment 44(10):547\u2013556","journal-title":"Oncology Research and Treatment"},{"issue":"Supplement_1","key":"10674_CR166","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1182\/blood-2019-122754","volume":"134","author":"NN Shah","year":"2019","unstructured":"Shah NN, Krishnan AY, Shah ND et al (2019) Preliminary results of a phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies. Blood 134(Supplement_1):5329","journal-title":"Blood"},{"key":"10674_CR167","doi-asserted-by":"publisher","first-page":"S572","DOI":"10.1016\/j.annonc.2024.08.815","volume":"35","author":"R Shapira-Frommer","year":"2024","unstructured":"Shapira-Frommer R, Sudo K, Harano K et al (2024) 754P Initial results from a first-in-human study of AZD5335, a folate receptor & #x3b1; (FR\u03b1)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC). Ann Oncol 35:S572\u2013S573","journal-title":"Ann Oncol"},{"issue":"3","key":"10674_CR168","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10637-016-0419-7","volume":"35","author":"GI Shapiro","year":"2017","unstructured":"Shapiro GI, Vaishampayan UN, LoRusso P et al (2017) First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs 35(3):315\u201323","journal-title":"Invest New Drugs"},{"issue":"4","key":"10674_CR169","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s10637-019-00768-6","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Wheler JJ, Einhorn L et al (2019) A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Invest New Drugs 37(4):738\u2013747","journal-title":"Invest New Drugs"},{"issue":"29","key":"10674_CR170","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Sands J, Yoh K et al (2023) First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2\u2013directed antibody-drug conjugate datopotamab deruxtecan in non\u2013small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol 41(29):4678\u20134687","journal-title":"J Clin Oncol"},{"key":"10674_CR171","doi-asserted-by":"publisher","first-page":"S551","DOI":"10.1016\/j.annonc.2024.08.782","volume":"35","author":"J Shu","year":"2024","unstructured":"Shu J, Zhu T, Huang Y et al (2024) 720MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): results from a phase I study. Ann Oncol 35:S551","journal-title":"Ann Oncol"},{"issue":"13","key":"10674_CR172","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19(13):3244\u20133254","journal-title":"J Clin Oncol"},{"issue":"9_Supplement","key":"10674_CR173","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO2-04-03","volume":"84","author":"E Song","year":"2024","unstructured":"Song E, Yao H, Sun M et al (2024) Abstract PO2-04-03: BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic breast cancer with HER2-positive\/low-expression and other solid tumors: results from a first-in-human phase 1 study. Cancer Res 84(9_Supplement):PO2-04-3-PO2--3","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"10674_CR174","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1182\/blood-2024-202866","volume":"144","author":"L Song","year":"2024","unstructured":"Song L, Qi J, Wang Z et al (2024) BL-M11D1, a novel CD33 antibody-drug conjugate (ADC), in patients with relapsed\/ refractory acute myeloid leukemia: initial results from first-in-human phase 1 study. Blood 144(Supplement 1):4260","journal-title":"Blood"},{"key":"10674_CR175","volume":"25","author":"MA Spinner","year":"2025","unstructured":"Spinner MA, Visco C, Thiruvengadam SK et al (2025) HL-998: first-in-human, open-label, phase 1 study of CD30-directed antibody-drug conjugate (ADC) with a topoisomerase 1 inhibitor payload, PF-08046044 (35C) in patients with relapsed\/refractory lymphomas: safety and preliminary efficacy from dose escalation. Clin Lymphoma Myeloma Leuk 25:S710-S1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10674_CR176","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","volume":"35","author":"LM Spring","year":"2024","unstructured":"Spring LM, Tolaney SM, Fell G et al (2024) Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial\u2606. Ann Oncol 35(3):293\u2013301","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"10674_CR177","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163509","volume":"140","author":"SE Spurgeon","year":"2022","unstructured":"Spurgeon SE, Mei M, Barr PM et al (2022) Waveline-001: updated results from a phase 1 dose escalation and cohort expansion study of zilovertamab vedotin (MK-2140) in non-Hodgkin lymphoma. Blood 140(Supplement 1):6640-1","journal-title":"Blood"},{"issue":"4","key":"10674_CR178","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","volume":"131","author":"EM Stein","year":"2018","unstructured":"Stein EM, Walter RB, Erba HP et al (2018) A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood 131(4):387\u201396","journal-title":"Blood"},{"issue":"33","key":"10674_CR179","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1200\/JCO.2018.78.7697","volume":"36","author":"JH Strickler","year":"2018","unstructured":"Strickler JH, Weekes CD, Nemunaitis J et al (2018) First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody\u2013drug conjugate targeting c-Met, in patients with advanced solid tumors. J Clin Oncol 36(33):3298\u20133306","journal-title":"J Clin Oncol"},{"key":"10674_CR180","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000890960.29449.17","author":"A Sureda-Balari","year":"2022","unstructured":"Sureda-Balari A, Terol MJ, Domingo-Dom\u00e8nech E et al (2022) T098: brentuximab vedotin plus ESHAP (BRESHAP) versus ESHAP in patients with relapsed or refractory classical Hodgkin\u2019s lymphoma. Interim results of the BRESELIBET prospective clinical trial. Hemasphere. https:\/\/doi.org\/10.1097\/01.HS9.0000890960.29449.17","journal-title":"Hemasphere"},{"key":"10674_CR181","doi-asserted-by":"publisher","first-page":"S589","DOI":"10.1016\/j.annonc.2021.08.1043","volume":"32","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Bedard P, Bang YJ et al (2021) 521P Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors. Ann Oncol 32:S589\u2013S590","journal-title":"Ann Oncol"},{"issue":"6","key":"10674_CR182","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","volume":"32","author":"NM Tannir","year":"2014","unstructured":"Tannir NM, Forero-Torres A, Ramchandren R et al (2014) Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 32(6):1246\u20131257","journal-title":"Invest New Drugs"},{"issue":"10","key":"10674_CR183","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clml.2024.05.017","volume":"24","author":"SK Thiruvengadam","year":"2024","unstructured":"Thiruvengadam SK, Mei MG, Chen L et al (2024) Phase I trial of brentuximab vedotin plus cyclosporine in relapsed\/refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 24(10):724\u201331.e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"IS","key":"10674_CR184","first-page":"30","volume":"19","author":"B Thwaites","year":"2023","unstructured":"Thwaites B, Ehikioya R (2023) Retrospective review of escalated antiemetic use and frequency of nausea and vomiting in breast cancer patients receiving trastuzumab-deruxtecan. J Oncol Pharm Pract 19(IS):30\u201331","journal-title":"J Oncol Pharm Pract"},{"issue":"21","key":"10674_CR185","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/1078-0432.CCR-20-1067","volume":"26","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Do KT, Eder JP et al (2020) A phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors. Clin Cancer Research 26(21):5588\u20135597","journal-title":"Clin Cancer Research"},{"issue":"2","key":"10674_CR186","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2003.05.137","volume":"21","author":"AW Tolcher","year":"2003","unstructured":"Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21(2):211\u2013222","journal-title":"J Clin Oncol"},{"key":"10674_CR187","doi-asserted-by":"publisher","first-page":"S474","DOI":"10.1016\/j.annonc.2021.08.542","volume":"32","author":"M Tsai","year":"2021","unstructured":"Tsai M, Han HS, Montero AJ et al (2021) 259P weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer. Ann Oncol 32:S474\u2013S475","journal-title":"Ann Oncol"},{"key":"10674_CR188","doi-asserted-by":"publisher","first-page":"v136","DOI":"10.1093\/annonc\/mdx367.042","volume":"28","author":"J Tsurutani","year":"2017","unstructured":"Tsurutani J, Doi T, Iwata H et al (2017) Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies. Ann Oncol 28:v136","journal-title":"Ann Oncol"},{"key":"10674_CR189","doi-asserted-by":"crossref","unstructured":"Tsurutani J, Park H, Doi T et al (2018) OA02.07 updated results of phase 1 study of DS-8201a in HER2-expressing or –mutated advanced non-small-cell lung cancer. J Thorac Oncol\u00a013(10): S324","DOI":"10.1016\/j.jtho.2018.08.244"},{"issue":"10","key":"10674_CR190","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1158\/1078-0432.CCR-19-1431","volume":"26","author":"R Vij","year":"2020","unstructured":"Vij R, Nath R, Afar DEH et al (2020) First-in-human phase I study of ABBV-838, an antibody\u2013drug conjugate targeting SLAMF7\/CS1 in patients with relapsed and refractory multiple myeloma. Clin Cancer Res 26(10):2308\u20132317","journal-title":"Clin Cancer Res"},{"issue":"S1","key":"10674_CR191","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bjh.18721","volume":"201","author":"M Walker","year":"2023","unstructured":"Walker M, Soutar R, Travers J (2023) Outcomes from real world use of belantamab at the Beatson Cancer Centre in relapsed\/refractory myeloma. Br J Haematol 201(S1):119\u2013185","journal-title":"Br J Haematol"},{"issue":"16_suppl","key":"10674_CR192","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1200\/JCO.2023.41.16_suppl.3017","volume":"41","author":"J Wang","year":"2023","unstructured":"Wang J, Duan J, Xing L et al (2023) ARTEMIS-001: phase 1 study of HS-20093, a B7-H3\u2013targeting antibody-drug conjugate, in patients with advanced solid tumor. J Clin Oncol 41(16_suppl):3017","journal-title":"J Clin Oncol"},{"issue":"8_Supplement","key":"10674_CR193","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT181","volume":"83","author":"J Wang","year":"2023","unstructured":"Wang J, Wu L, Song Z et al (2023) Abstract CT181: a first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors. Cancer Res 83(8_Supplement):CT181-CT","journal-title":"Cancer Res"},{"key":"10674_CR194","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2020-139468","volume":"136","author":"M Wang","year":"2020","unstructured":"Wang M, Barrientos JC, Furman RR et al (2020) VLS-101, a ROR1-Targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical efficacy in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma. Blood 136:13\u201314","journal-title":"Blood"},{"issue":"16_suppl","key":"10674_CR195","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1200\/JCO.2025.43.16_suppl.1090","volume":"43","author":"S Wang","year":"2025","unstructured":"Wang S, Zhang Q, Yang J et al (2025) Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent\/metastatic breast cancer: results from a phase 1b study. J Clin Oncol 43(16_suppl):1090","journal-title":"J Clin Oncol"},{"issue":"11","key":"10674_CR196","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.29271\/jcpsp.2024.11.1378","volume":"34","author":"X Wang","year":"2024","unstructured":"Wang X, Xue Y (2024) The efficacy and safety of trastuzumab in the metastatic breast cancer. J Coll Physicians Surg Pak 34(11):1378\u20131381","journal-title":"J Coll Physicians Surg Pak"},{"issue":"16_suppl","key":"10674_CR197","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gong J, Lin R et al (2023) First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors. J Clin Oncol 41(16_suppl):3016","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR198","doi-asserted-by":"publisher","first-page":"8521","DOI":"10.1200\/JCO.2025.43.16_suppl.8521","volume":"43","author":"SN Waqar","year":"2025","unstructured":"Waqar SN, Cuppens K, Campelo RG et al (2025) First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a\/mNSCLC): results from TROPION-Lung04 (cohort 5). J Clin Oncol 43(16_suppl):8521.\u00a0https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.8521","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10674_CR199","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1182\/blood-2022-162406","volume":"140","author":"P Westervelt","year":"2022","unstructured":"Westervelt P, Kebriaei P, Juckett M et al (2022) Mgta-117, an anti-CD117 antibody-drug conjugated with amanitin, in participants with relapsed\/refractory adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB): safety, pharmacokinetics and pharmacodynamics initial findings from a phase 1\/2 study. Blood 140(Supplement 1):2117\u20132119","journal-title":"Blood"},{"issue":"Supplement 1","key":"10674_CR200","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1182\/blood-2023-180141","volume":"142","author":"R Williams","year":"2023","unstructured":"Williams R, Miller L, Massaro S et al (2023) Anti-leukemic activity of luveltamab tazevibulin (LT, STRO-002), a Novel folate receptor-\u03b1 (FR-\u03b1)-targeting antibody drug conjugate (ADC) in relapsed\/refractory CBF2AT3::GLIS2 AML. Blood 142(Supplement 1):4295","journal-title":"Blood"},{"issue":"16_suppl","key":"10674_CR201","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1200\/JCO.2025.43.16_suppl.3039","volume":"43","author":"IS Winer","year":"2025","unstructured":"Winer IS, Cloven N, Richardson DL et al (2025) Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: first disclosure from dose expansion cohort B2 of the GTC1184-01 study. J Clin Oncol 43(16_suppl):3039","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR202","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1200\/JCO.2025.43.16_suppl.1102","volume":"43","author":"F Wu","year":"2025","unstructured":"Wu F, Chu Q, Xu Q et al (2025) Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients (pts) with advanced triple-negative breast cancer (TNBC) and other solid tumors: results from the phase 1 study. J Clin Oncol 43(16_suppl):1102","journal-title":"J Clin Oncol"},{"key":"10674_CR203","doi-asserted-by":"crossref","unstructured":"Wu J, Zhang J, Du Y et al (2024) Abstract PS08\u201307: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic breast cancer and other solid tumor: results from a phase 1 study. Cancer Res\u00a084(9_Supplement): PS08\u20137-PS-7","DOI":"10.1158\/1538-7445.SABCS23-PS08-07"},{"key":"10674_CR204","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1016\/j.annonc.2023.09.558","volume":"34","author":"J Wu","year":"2023","unstructured":"Wu J, Zhang J, Li H et al (2023) 381O first-in-human\/phase I trial of HS-20089, a B7\u2013H4 ADC, in patients with advanced solid tumors. Ann Oncol 34:S336","journal-title":"Ann Oncol"},{"key":"10674_CR205","doi-asserted-by":"crossref","unstructured":"Xu H, Sheng X, Zhou L et al (2022) A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol 40(16_suppl): 4519-","DOI":"10.1200\/JCO.2022.40.16_suppl.4519"},{"issue":"23","key":"10674_CR206","doi-asserted-by":"publisher","first-page":"21159","DOI":"10.1002\/cam4.6680","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu J, Zhang H, Zhang L et al (2023) Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: a multicenter, retrospective clinical study. Cancer Med 12(23):21159\u201321171","journal-title":"Cancer Med"},{"key":"10674_CR207","doi-asserted-by":"crossref","unstructured":"Xu M, Kong Y, Chen R et al (2025) RC48-ADC combined with radiotherapy and immunotherapy as salvage therapy for advanced solid tumors with HER2 expression: a multicenter, phase II trial. J Clin Oncol\u00a043(16_suppl): 3032-","DOI":"10.1200\/JCO.2025.43.16_suppl.3032"},{"key":"10674_CR208","doi-asserted-by":"crossref","unstructured":"Yao H, Liu J, Zeng Y et al (2025) First-in-human study of JSKN016, a bispecific anti-TROP2\/HER3 antibody drug conjugate (ADC): antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results. J Clin Oncol\u00a043(16_suppl): e13138-e","DOI":"10.1200\/JCO.2025.43.16_suppl.e13138"},{"issue":"23","key":"10674_CR209","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1182\/blood.V126.23.814.814","volume":"126","author":"CA Yasenchak","year":"2015","unstructured":"Yasenchak CA, Halwani A, Advani R et al (2015) Brentuximab vedotin with RCHOP as frontline therapy in patients with high-intermediate\/high-risk diffuse large B cell lymphoma (DLBCL): results from an ongoing phase 2 study. Blood 126(23):814","journal-title":"Blood"},{"key":"10674_CR210","doi-asserted-by":"publisher","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2044","volume":"35","author":"D Ye","year":"2024","unstructured":"Ye D, Bian X, Yang T et al (2024) 1959O BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC). Ann Oncol 35:S1133","journal-title":"Ann Oncol"},{"issue":"8","key":"10674_CR211","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1111\/cas.15443","volume":"113","author":"K Yonemori","year":"2022","unstructured":"Yonemori K, Kuboki Y, Hasegawa K et al (2022) Tisotumab vedotin in Japanese patients with recurrent\/metastatic cervical cancer: results from the innovaTV 206 study. Cancer Sci 113(8):2788\u20132797","journal-title":"Cancer Sci"},{"issue":"19","key":"10674_CR212","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Fau Bartlett Nl, Leonard -, JP, Leonard Jp Fau - Kennedy DA et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812\u201321","journal-title":"N Engl J Med"},{"issue":"18","key":"10674_CR213","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20132189","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR214","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1200\/JCO.2024.42.16_suppl.3013","volume":"42","author":"J Zhang","year":"2024","unstructured":"Zhang J, Liu R, Gao S et al (2024) 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: results from a phase 1\/2a study. J Clin Oncol 42(16_suppl):3013","journal-title":"J Clin Oncol"},{"key":"10674_CR215","doi-asserted-by":"publisher","first-page":"S758","DOI":"10.1016\/j.annonc.2023.09.2350","volume":"34","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ma Y, Zhao Y et al (2023) 1316MO BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: updated results from first-in-human phase I study. Ann Oncol 34:S758","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10674_CR216","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1200\/JCO.2025.43.16_suppl.5517","volume":"43","author":"S Zhang","year":"2025","unstructured":"Zhang S, Jia H, Liu J et al (2025) Safety and efficacy of BAT8006, a folate receptor \u03b1 (FR\u03b1) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: update on the dose optimization\/expansion cohort of BAT-8006-001-CR trial. J Clin Oncol 43(16_suppl):5517","journal-title":"J Clin Oncol"},{"key":"10674_CR217","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1016\/j.annonc.2024.08.672","volume":"35","author":"H Zhao","year":"2024","unstructured":"Zhao H, Ma Y, Meng X et al (2024) 605O YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: results from a first-in-human phase I study. Ann Oncol 35:S485","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10674_CR218","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1200\/JCO.2025.43.16_suppl.3024","volume":"43","author":"J Zhao","year":"2025","unstructured":"Zhao J, Dinglin X-X, Ji Y et al (2025) BAT8008, a TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: results from a phase 1 study. J Clin Oncol 43(16_suppl):3024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10674_CR219","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.2025.43.16_suppl.107","volume":"43","author":"R Zhong","year":"2025","unstructured":"Zhong R, Yan M, Wang Q et al (2025) Phase 1 trial of SHR-A2102, a nectin-4\u2013directed antibody drug conjugate (ADC), in advanced solid tumors. J Clin Oncol 43(16_suppl):107","journal-title":"J Clin Oncol"},{"issue":"10","key":"10674_CR220","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jtho.2024.09.081","volume":"19","author":"C Zhou","year":"2024","unstructured":"Zhou C, Yang B, Sun Y et al (2024) OA16.04 preliminary results from a FIH study of GQ1005, a novel HER2-ADC, in patients with advanced HER2-expressing solid tumors and HER2-mutated NSCLC. J Thorac Oncol 19(10):S46","journal-title":"J Thorac Oncol"},{"issue":"6_suppl","key":"10674_CR221","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1200\/JCO.2022.40.6_suppl.515","volume":"40","author":"L Zhou","year":"2022","unstructured":"Zhou L, Xu H, Li S et al (2022) Study RC48-C014: preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol 40(6_suppl):515","journal-title":"J Clin Oncol"},{"key":"10674_CR222","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"ASM Mosa","year":"2020","unstructured":"Mosa ASM, Hossain AM, Lavoie BJ, Yoo I (2020) Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol 11:329","journal-title":"Front Pharmacol"},{"issue":"8","key":"10674_CR223","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.annonc.2023.05.004","volume":"34","author":"M Oliveira","year":"2023","unstructured":"Oliveira M, Falato C, Cejalvo JM, Margel\u00ed Vila M, Tolosa P, Salvador-Bofill FJ, Cruz J, Arumi M, Luna AM, Guerra JA, Vidal M, Mart\u00ednez-S\u00e1ez O, Par\u00e9 L, Gonz\u00e1lez-Farr\u00e9 B, Sanfeliu E, Ciruelos E, Espinosa-Bravo M, Pernas S, Izarzugaza Y, Esker S, Fan PD, Parul P, Santhanagopal A, Sellami D, Villacampa G, Ferrero-Cafiero JM, Pascual T, Prat A (2023) Patritumab deruxtecan in untreated hormone receptor-positive\/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Ann Oncol 34(8):670\u2013680. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.004\/","journal-title":"Ann Oncol"},{"issue":"6","key":"10674_CR224","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28(6):1260\u20131267","journal-title":"Ann Oncol"},{"issue":"12","key":"10674_CR225","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143\u20131154","journal-title":"N Engl J Med"},{"issue":"1","key":"10674_CR226","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10674-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10674-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10674-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:03:58Z","timestamp":1778691838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10674-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":227,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10674"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10674-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}],"article-number":"486"}}